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THE STATUS OF QUALITY OF LIFE DATA IN
HEALTH TECHNOLOGY ASSESSMENTS:
EVIDENCE FROM PUBLISHED NICE
APPRAISALS
Kind P
Outcomes Research Group,York, UK
The requirements for health technology assessments con-
ducted for the National Institute for Clinical Effectiveness
(NICE) are similar to those deemed applicable by other
groups (for example the Washington Panel). Beneﬁts 
are represented in terms of quality-adjusted life years
(QALYs) where the quality adjustment is based on the
utility weights of the relevant reference population. 
A single index, utility-weighted scoring function that cap-
tures the preferences of the general population is prob-
lematic. Access to such a weighting system is typically
mediated through quality of life (QoL) data that capture
the beneﬁts of therapy. Where QoL data do not meet
these requirements then alternative methods have to be
adopted.
OBJECTIVES: To assess the status of QoL data in the
published NICE record and to review the procedures used
to estimate utilities based on those data.
METHODS: The 31 assessment reports published by
NICE in the period 1999–2001 were systematically
reviewed. Particular attention was paid to information
provided about QoL measures incorporated in the studies
referenced by the appraisal. Of special note was the type
of measure (i.e. index or proﬁle), its weighting system and
the source of reference values.
RESULTS: QoL data was reported with varying com-
pleteness. This contrasts with the data abstraction cover-
ing other aspects of the appraisal. Methods used to weight
QoL data ranged from the deliberation of expert panels
to the use of standarised QoL measures with utility
weights elicited from the general population. Evidence 
of subjective assessment of QALY estimates included 
their being “based on reasonable assumptions using well-
accepted measures”.
CONCLUSIONS: Evidence of the variability in the
quality of QoL data and their use in QALY calculations
indicates the need for clearer guidance and rigour in
reporting and analysis. Findings impact on all parties to
this form of technology assessment.
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1Guido Wendland, Cologne, NW, Germany; 2University of
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OBJECTIVES: Despite their surprisingly good ﬁt of
current mortality data, Gompertz-functions are rather
seldom used in outcome research. The main objective is
to show some interesting methodological features of the
Gompertz function encouraging a more wide-spread use
in modeling mortality rates beyond the time frame of clin-
ical trials.
METHODS: Current mortality data of the Statistical
Yearbook of Germany are closely ﬁtted by Gompertz
functions (Rx = R0 exp(bx), x = age) which involves esti-
mating parameters b und R0 by non-linear iterative
regression. Several authors have observed that in a series
of Gompertz-functions from the same underlying popu-
lation (i.e. life tables from different years, different sub-
groups, different regions etc.) the two parameters are
closely related as: lnR0 = ab + b, where a < 0, b Œ IR.
Based on this relation, it is shown how to determine Gom-
pertz functions for speciﬁc study cohorts by specifying a
standardised mortality ratio (SMR) at a certain age. In
practical applications this SMR can be estimated from
clinical trials data.
RESULTS: All Gompertz-functions satisfying the relation
lnR0 = ab + b intersect at (-a, exp(b)). If the SMR is ﬁxed
at an age of x¢ then a Gompertz-function satisfying this
condition is given by b2 = ln(SMR)/(x¢ + a) + b1, and R20
= exp(ab2) exp(b), where (b2, R20) is the pair of parame-
ters of the new Gompertz-function, and the pair (b1, R10)
belongs to the baseline Gompertz-function. Furthermore
it holds that the hazard ratio at any age is given by the
ratio (R20/R10)x/a+1.
CONCLUSIONS: The more frequent use of Gompertz-
Functions in the area of modeling is motivated by the
good ﬁt of mortality data in the general population. 
Furthermore, this analysis shows how these results can 
be extended to speciﬁc subgroups of patients, when clin-
ical trials data only provide little mortality data. The
analysis of high-risk groups in disease prevention seems
a sensible context for applying these results.
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A UTILITY-MAXIMISATION MODEL OF CHOICE
BETWEEN MEDICAL INTERVENTIONS
INVOLVING RISK
Walshe R
University of Cologne, Cologne, Germany
OBJECTIVES: To develop a utility-maximisation model
of choice between alternative treatments of speciﬁc dis-
orders on the basis of microeconomic consumption
theory. The model is to take into account patients’ pref-
erences for clinical procedures, possible outcomes and
risks involved in alternative treatments.
METHODS: The optimisation problem facing a patient
is presented by geometrical and algebraic analysis using
an ordinal von Neumann Morgenstern (vNM) utility
function in a simple example involving two treatment
alternatives, T1 and T2. As the treatments are perfect sub-
stitutes, the ratio of marginal utilities (dT2/dT1) which
determines the slope of a patient’s indifference curves is
constant and can be identiﬁed by means of a modiﬁed
standard gamble (MSG). By including relative prices of
